Michael Hodges
Consultant / Advisor at EFFECTOR THERAPEUTICS, INC.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Stephen Worland | M | 66 | 12 years | |
| Lilly deSouza Burr | F | - |
Adjuvant Capital LP
 Adjuvant Capital LP Investment ManagersFinance Adjuvant Capital LP (Adjuvant Capital) is a private equity and venture capital firm founded in 2018 by Glenn Rockman, Kabeer Aziz and Charlie Petty. The firm is headquartered in New York. | 5 years |
| Roberto de Ponti | M | - |
Claris Ventures Sgr SpA
 Claris Ventures Sgr SpA Investment ManagersFinance Claris Ventures Sgr SpA (Claris Ventures) is a venture capital firm founded in 2019 by Pietro Puglisi and Ciro Spedaliere. The firm is headquartered in Turin, Italy. | 4 years |
| Brian Gallagher | M | 54 | 4 years | |
| Pietro Puglisi | M | - |
Resalis Therapeutics SRL
 Resalis Therapeutics SRL Miscellaneous Commercial ServicesCommercial Services Resalis Therapeutics SRL is a company that focuses on developing a transformative metabolic disease approach to target obesity and fatty liver disease. The company is based in Turin, Italy. The Italian company's lead program, RES-010, is a safe and convenient treatment that provides disease-modifying therapeutic impact, including durable weight loss and reduction of hepatic steatosis. The CEO of the company is Eva Castagnetti.
Claris Ventures Sgr SpA
Claris Ventures Sgr SpA Investment ManagersFinance Claris Ventures Sgr SpA (Claris Ventures) is a venture capital firm founded in 2019 by Pietro Puglisi and Ciro Spedaliere. The firm is headquartered in Turin, Italy. | 5 years |
| Barbara Klencke | M | 66 | 3 years | |
| Kristen Harrington-Smith | F | 51 | 2 years | |
| Mike Hodges | M | - |
Resalis Therapeutics SRL
Resalis Therapeutics SRL Miscellaneous Commercial ServicesCommercial Services Resalis Therapeutics SRL is a company that focuses on developing a transformative metabolic disease approach to target obesity and fatty liver disease. The company is based in Turin, Italy. The Italian company's lead program, RES-010, is a safe and convenient treatment that provides disease-modifying therapeutic impact, including durable weight loss and reduction of hepatic steatosis. The CEO of the company is Eva Castagnetti. | - |
| Riccardo Panella | M | - |
Resalis Therapeutics SRL
Resalis Therapeutics SRL Miscellaneous Commercial ServicesCommercial Services Resalis Therapeutics SRL is a company that focuses on developing a transformative metabolic disease approach to target obesity and fatty liver disease. The company is based in Turin, Italy. The Italian company's lead program, RES-010, is a safe and convenient treatment that provides disease-modifying therapeutic impact, including durable weight loss and reduction of hepatic steatosis. The CEO of the company is Eva Castagnetti. | - |
| Charlie Petty | M | - |
Adjuvant Capital LP
Adjuvant Capital LP Investment ManagersFinance Adjuvant Capital LP (Adjuvant Capital) is a private equity and venture capital firm founded in 2018 by Glenn Rockman, Kabeer Aziz and Charlie Petty. The firm is headquartered in New York. | 6 years |
| Glenn Rockman | M | 43 |
Adjuvant Capital LP
Adjuvant Capital LP Investment ManagersFinance Adjuvant Capital LP (Adjuvant Capital) is a private equity and venture capital firm founded in 2018 by Glenn Rockman, Kabeer Aziz and Charlie Petty. The firm is headquartered in New York. | 6 years |
| Christopher Ehrlich | M | 54 | 3 years | |
| Ciro Spedaliere | M | - |
Claris Ventures Sgr SpA
Claris Ventures Sgr SpA Investment ManagersFinance Claris Ventures Sgr SpA (Claris Ventures) is a venture capital firm founded in 2019 by Pietro Puglisi and Ciro Spedaliere. The firm is headquartered in Turin, Italy. | 5 years |
| Michael Byrnes | M | 47 | 4 years | |
| Kabeer Aziz | M | 34 |
Adjuvant Capital LP
Adjuvant Capital LP Investment ManagersFinance Adjuvant Capital LP (Adjuvant Capital) is a private equity and venture capital firm founded in 2018 by Glenn Rockman, Kabeer Aziz and Charlie Petty. The firm is headquartered in New York. | 6 years |
| Elizabeth Bhatt | F | 56 | 3 years | |
| Laura Iris Ferro | M | 72 |
Claris Ventures Sgr SpA
Claris Ventures Sgr SpA Investment ManagersFinance Claris Ventures Sgr SpA (Claris Ventures) is a venture capital firm founded in 2019 by Pietro Puglisi and Ciro Spedaliere. The firm is headquartered in Turin, Italy. | 4 years |
| Manilo Marocco | M | 66 |
Claris Ventures Sgr SpA
Claris Ventures Sgr SpA Investment ManagersFinance Claris Ventures Sgr SpA (Claris Ventures) is a venture capital firm founded in 2019 by Pietro Puglisi and Ciro Spedaliere. The firm is headquartered in Turin, Italy. | - |
| Kim Kamdar | M | 56 |
Adjuvant Capital LP
Adjuvant Capital LP Investment ManagersFinance Adjuvant Capital LP (Adjuvant Capital) is a private equity and venture capital firm founded in 2018 by Glenn Rockman, Kabeer Aziz and Charlie Petty. The firm is headquartered in New York. | - |
| Cristina Tumiatti | F | - |
Claris Ventures Sgr SpA
Claris Ventures Sgr SpA Investment ManagersFinance Claris Ventures Sgr SpA (Claris Ventures) is a venture capital firm founded in 2019 by Pietro Puglisi and Ciro Spedaliere. The firm is headquartered in Turin, Italy. | 4 years |
| Gene Yeo | M | - | - | |
| Fabio DAgostino | M | - |
Claris Ventures Sgr SpA
Claris Ventures Sgr SpA Investment ManagersFinance Claris Ventures Sgr SpA (Claris Ventures) is a venture capital firm founded in 2019 by Pietro Puglisi and Ciro Spedaliere. The firm is headquartered in Turin, Italy. | 5 years |
| Douglas Warner | M | 52 | 2 years | |
| Peter Patriarca | M | - |
Adjuvant Capital LP
Adjuvant Capital LP Investment ManagersFinance Adjuvant Capital LP (Adjuvant Capital) is a private equity and venture capital firm founded in 2018 by Glenn Rockman, Kabeer Aziz and Charlie Petty. The firm is headquartered in New York. | - |
| Jim Robinson | M | - |
Adjuvant Capital LP
Adjuvant Capital LP Investment ManagersFinance Adjuvant Capital LP (Adjuvant Capital) is a private equity and venture capital firm founded in 2018 by Glenn Rockman, Kabeer Aziz and Charlie Petty. The firm is headquartered in New York. | - |
| Christian Mandl | M | - |
Adjuvant Capital LP
Adjuvant Capital LP Investment ManagersFinance Adjuvant Capital LP (Adjuvant Capital) is a private equity and venture capital firm founded in 2018 by Glenn Rockman, Kabeer Aziz and Charlie Petty. The firm is headquartered in New York. | 5 years |
| Sophie Allauzen | F | - |
Adjuvant Capital LP
Adjuvant Capital LP Investment ManagersFinance Adjuvant Capital LP (Adjuvant Capital) is a private equity and venture capital firm founded in 2018 by Glenn Rockman, Kabeer Aziz and Charlie Petty. The firm is headquartered in New York. | - |
| Gerard Cunningham | M | - |
Adjuvant Capital LP
Adjuvant Capital LP Investment ManagersFinance Adjuvant Capital LP (Adjuvant Capital) is a private equity and venture capital firm founded in 2018 by Glenn Rockman, Kabeer Aziz and Charlie Petty. The firm is headquartered in New York. | 4 years |
| David Washer | M | - |
Adjuvant Capital LP
Adjuvant Capital LP Investment ManagersFinance Adjuvant Capital LP (Adjuvant Capital) is a private equity and venture capital firm founded in 2018 by Glenn Rockman, Kabeer Aziz and Charlie Petty. The firm is headquartered in New York. | 3 years |
| Curt LaBelle | M | 53 |
Adjuvant Capital LP
Adjuvant Capital LP Investment ManagersFinance Adjuvant Capital LP (Adjuvant Capital) is a private equity and venture capital firm founded in 2018 by Glenn Rockman, Kabeer Aziz and Charlie Petty. The firm is headquartered in New York. | - |
| Mark Densel | M | - | 6 years | |
| Caroline Loewy | F | 58 | 1 years | |
| Michael Bridges | M | - |
Wright State University (Ohio)
| 12 years |
| Mark Sullivan | M | - |
Adjuvant Capital LP
Adjuvant Capital LP Investment ManagersFinance Adjuvant Capital LP (Adjuvant Capital) is a private equity and venture capital firm founded in 2018 by Glenn Rockman, Kabeer Aziz and Charlie Petty. The firm is headquartered in New York. | 4 years |
| Michael Chang | M | - |
Adjuvant Capital LP
Adjuvant Capital LP Investment ManagersFinance Adjuvant Capital LP (Adjuvant Capital) is a private equity and venture capital firm founded in 2018 by Glenn Rockman, Kabeer Aziz and Charlie Petty. The firm is headquartered in New York. | 6 years |
| Chris LeMasters | M | - |
Amplyx Pharmaceuticals, Inc.
 Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | 4 years |
| Jenny Yip | F | - |
Adjuvant Capital LP
Adjuvant Capital LP Investment ManagersFinance Adjuvant Capital LP (Adjuvant Capital) is a private equity and venture capital firm founded in 2018 by Glenn Rockman, Kabeer Aziz and Charlie Petty. The firm is headquartered in New York. | 5 years |
| John Grundy | M | - | - | |
| Timothy Booher | M | - |
US Air Force
| 3 years |
| Christine Esau | M | - | - | |
| Mayank J. Gandhi | M | 47 | 2 years | |
| Evelyn Yanatos | F | - |
Adjuvant Capital LP
Adjuvant Capital LP Investment ManagersFinance Adjuvant Capital LP (Adjuvant Capital) is a private equity and venture capital firm founded in 2018 by Glenn Rockman, Kabeer Aziz and Charlie Petty. The firm is headquartered in New York. | - |
| Jennifer Doudna | M | 60 | - | |
| Dena Marrinucci | M | - |
Adjuvant Capital LP
Adjuvant Capital LP Investment ManagersFinance Adjuvant Capital LP (Adjuvant Capital) is a private equity and venture capital firm founded in 2018 by Glenn Rockman, Kabeer Aziz and Charlie Petty. The firm is headquartered in New York. | 3 years |
| Luca Melindo | M | 53 |
Claris Ventures Sgr SpA
Claris Ventures Sgr SpA Investment ManagersFinance Claris Ventures Sgr SpA (Claris Ventures) is a venture capital firm founded in 2019 by Pietro Puglisi and Ciro Spedaliere. The firm is headquartered in Turin, Italy. | - |
| Padmanabh Chivukula | M | 45 | - | |
| Antonio Leone | M | - |
Resalis Therapeutics SRL
Resalis Therapeutics SRL Miscellaneous Commercial ServicesCommercial Services Resalis Therapeutics SRL is a company that focuses on developing a transformative metabolic disease approach to target obesity and fatty liver disease. The company is based in Turin, Italy. The Italian company's lead program, RES-010, is a safe and convenient treatment that provides disease-modifying therapeutic impact, including durable weight loss and reduction of hepatic steatosis. The CEO of the company is Eva Castagnetti. | - |
| Adam Mullick | M | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Mitchell Mutz | M | 61 |
Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | 10 years |
| Robert Pinizzotto | M | - |
Wright State University (Ohio)
| 12 years |
| Michael Grey | M | 71 |
Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | 6 years |
| Jill Howe | F | 48 |
Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | 1 years |
| Chris Moncourtois | M | - |
East Carolina University
| 7 years |
| Alan Fuhrman | M | 67 |
Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | 3 years |
| Ronald Reichers | M | - |
Wright State University (Ohio)
| 12 years |
| Lynsey Shepard | F | - |
Wright State University (Ohio)
| 1 years |
| Greg Hall | M | - |
East Carolina University
| 4 years |
| Danny Stillion | M | - |
East Carolina University
| 3 years |
| Charlie Lee Tingen | M | 54 |
East Carolina University
| 4 years |
| John Cameron | M | - |
East Carolina University
| 4 years |
| Jennifer Christie | M | - |
East Carolina University
| 1 years |
| Kevin Clark Stallings | M | 56 |
East Carolina University
| 4 years |
| John May | M | 51 |
East Carolina University
| 4 years |
| David J. Nett | M | - |
East Carolina University
| 4 years |
| Elisa Torchia | F | - |
Claris Ventures Sgr SpA
Claris Ventures Sgr SpA Investment ManagersFinance Claris Ventures Sgr SpA (Claris Ventures) is a venture capital firm founded in 2019 by Pietro Puglisi and Ciro Spedaliere. The firm is headquartered in Turin, Italy. | 4 years |
| Chris Chase | M | - |
East Carolina University
| 4 years |
| Michael G. Leemhuis | M | 75 |
East Carolina University
| 1 years |
| Seth M. Wilfong | M | 43 |
East Carolina University
| 14 years |
| Gary Mitchell Gore | M | - |
East Carolina University
| 4 years |
| Anna Griffin | F | 53 |
East Carolina University
| 4 years |
| Stayce Harris | F | 64 |
US Air Force
| 3 years |
| Michael Timm | M | - |
Wright State University (Ohio)
| 4 years |
| Tim Xu | M | - |
Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | - |
| Brian Sanders | M | - |
East Carolina University
| 4 years |
| Charles McTiernan | M | - |
East Carolina University
| 4 years |
| Heather A. Wilson | M | 63 |
US Air Force
| - |
| Harry L. Smith | M | 54 |
East Carolina University
| 4 years |
| Dwight V. Neese | M | 73 |
East Carolina University
| 4 years |
| Christle Powell | F | - |
East Carolina University
| 4 years |
| Maha Katabi | M | 50 |
Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | 1 years |
| David Havens | M | - |
East Carolina University
| 4 years |
| Ed Mathers Mathers | M | 64 |
Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | 6 years |
| Guy Buck | M | - |
East Carolina University
| 4 years |
| Jeff Christenat | M | - |
East Carolina University
| 4 years |
| John Powell | M | - |
East Carolina University
| 4 years |
| Mark Vaughn | M | - |
East Carolina University
| 4 years |
| Tully M. Ryan | M | - |
East Carolina University
| 4 years |
| Jeff Boltinhouse | M | - |
East Carolina University
| 4 years |
| Scott Newton | M | - |
East Carolina University
| 4 years |
| Gregory Taylor | M | - |
East Carolina University
| 4 years |
| Todd Patton | M | 56 |
East Carolina University
| 4 years |
| Elizabeth Gordon | M | - |
Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | 6 years |
| Brian J. Miller | M | - |
East Carolina University
| 4 years |
| Jeff Porter | M | 60 |
East Carolina University
| 2 years |
| Karen Joy Shaw | M | 68 |
Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | - |
| Vincent N. DiRenzo | M | - |
East Carolina University
| 1 years |
| Kenneth Evans | M | 61 |
East Carolina University
| 4 years |
| Chase Oakley | M | - |
Wright State University (Ohio)
| 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 81 | 82.65% |
| Italy | 12 | 12.24% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Michael Hodges
- Personal Network
